Tonix Posts $2.44 Q2 Loss Per Share, Cash Burn in Focus
TNXP sits 25% above its 52-week low of $9.4.
Summary
Tonix reported a Q2 loss of $2.44 per share, deepening from prior quarters. The company continues to burn cash while advancing its pipeline, with a going concern warning still in place. Recent milestones include FDA alignment on a Lyme disease study and expanded TONMYA coverage, but the financial runway remains tight. The Q2 figure provides a concrete update on the burn rate heading into the second half.
Updates
· SEC 10-Q — Cash and cash equivalents were $176.2 million at June 30, 2026, and the company expects its cash runway to extend into early Q2 2027. Net loss for Q2 was $40.6 million, with product revenue of $13.5 million.
At the time of this announcement, TNXP was trading at $11.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.8M. The 52-week trading range was $9.40 to $69.97. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.